Objective and subjective effects of treatment for testicular cancer on sexual function.

作者: Van Basten , Van Driel , Hoekstra , Sleijfer , Van De Wiel

DOI: 10.1046/J.1464-410X.1999.00262.X

关键词:

摘要: Objective  To determine whether the treatment of patients with testicular cancer, using cisplatin combined etoposide and bleomycin (BEP) after orchidectomy in those disseminated disease, causes changes sex hormones penile vascularization, possibly related to sexual dysfunction. Patients methods  Ten treated BEP were compared 11 undergoing alone followed by surveillance. Sex hormone levels analysed cavernosal artery duplex ultrasonography performed before at 6 12 months afterward. Patients questioned about their function. After 1 year, a visual erotic stimulation (VES) test was assess rigidity. Results  In contrast surveillance group, BEP-treated had higher follicle-stimulating (4.6 vs 26.5 U/L) luteinizing (1.4 8.2 levels, lower testosterone (21.1 14.7 nmol/L) than baseline. At most compensated hypergonadotrophic eugonadism, but Leydig cell function recovered. Changes peak flow velocities induced local injection papaverine/phentolamine showed no difference between groups orchidectomy. Loss libido erectile dysfunction reported more frequently patients. However, year treatment, satisfying life VES resulted rigid erection nearly all The could not be explained plasma or diminished blood velocities. Conclusions  After being diagnosed morbidity is considerable, within some improvement may expected. induces transient this recovers. Although symptoms angiopathy, seems unaffected. These findings normal VES-evoked rigidity suggest that psychological organically BEP.

参考文章(32)
Grieteke Jonker-Pool, Jean P. van Basten, Harald J. Hoekstra, Mels F. van Driel, Dirk Th. Sleijfer, Heimen Schraffordt Koops, Harry B.�M. van de Wiel, Sexual functioning after treatment for testicular cancer Cancer. ,vol. 80, pp. 454- 464 ,(1997) , 10.1002/(SICI)1097-0142(19970801)80:3<454::AID-CNCR13>3.0.CO;2-W
L H Einhorn, Treatment of testicular cancer: a new and improved model. Journal of Clinical Oncology. ,vol. 8, pp. 1777- 1781 ,(1990) , 10.1200/JCO.1990.8.11.1777
H Lampe, A Horwich, A Norman, J Nicholls, D P Dearnaley, Fertility after chemotherapy for testicular germ cell cancers. Journal of Clinical Oncology. ,vol. 15, pp. 239- 245 ,(1997) , 10.1200/JCO.1997.15.1.239
J P van Basten, H J Hoekstra, M F van Driel, H S Koops, J H Droste, G Jonker-Pool, H B van de Wiel, D T Sleijfer, Sexual dysfunction in nonseminoma testicular cancer patients is related to chemotherapy-induced angiopathy Journal of Clinical Oncology. ,vol. 15, pp. 2442- 2448 ,(1997) , 10.1200/JCO.1997.15.6.2442
Y Arai, M Kawakita, Y Okada, O Yoshida, Sexuality and fertility in long-term survivors of testicular cancer Journal of Clinical Oncology. ,vol. 15, pp. 1444- 1448 ,(1997) , 10.1200/JCO.1997.15.4.1444
Gerald A. Leblanc, Philip W. Kantoff, Sze-Fong Ng, Emil Frei, David J. Waxman, Hormonal Perturbations in Patients With Testicular Cancer Treated With Cisplatin Cancer. ,vol. 69, pp. 2306- 2310 ,(1992) , 10.1002/1097-0142(19920501)69:9<2306::AID-CNCR2820690917>3.0.CO;2-F
A. Burnett, C. Lowenstein, D. Bredt, T. Chang, S. Snyder, Nitric oxide: a physiologic mediator of penile erection Science. ,vol. 257, pp. 401- 403 ,(1992) , 10.1126/SCIENCE.1378650
Ramona M. Chapman, Male Gonadal Dysfunction in Hodgkin's Disease JAMA. ,vol. 245, pp. 1323- 1328 ,(1981) , 10.1001/JAMA.1981.03310380027020
S Bhasin, Clinical review 34: Androgen treatment of hypogonadal men. The Journal of Clinical Endocrinology and Metabolism. ,vol. 74, pp. 1221- 1225 ,(1992) , 10.1210/JCEM.74.6.1592862